
Bharat Biotech Cuts MOSQIVAC Price by 40%
The story in brief
Bharat Biotech reduced the price of MOSQIVAC by 40% to protect an additional 1 million children. The move, part of an agreement with UNICEF and Gavi, is expected to save USD 50 million. The malaria vaccine, developed by GSK and manufactured by Bharat Biotech, aims to combat the urgent need for action against malaria.